Guiding decisions to omit radiation after breast conserving surgery for invasive breast cancer

Synopsis

The use of genomic-based signatures is now commonplace in guiding systemic therapy decisions after numerous trials demonstrated the efficacy and clinical utility of these tests as both prognostic and predictive biomarkers of patients’ outcomes and response to systemic therapy. Currently, similar genomic-based signatures have not yet been validated for clinical use to guide radiation decisions for local control endpoints, though numerous efforts are underway to validate these signatures. Both previously derived signatures (e.g. Oncotype Dx®, ProSigna, IHC based subtyping, etc.) and radiation specific signatures (e.g. DBCG-RT, RSI, Radiotype Dx, ARTIC, etc.) are currently being evaluated in this space, and this session will review the current state of the field and planned and ongoing efforts to validate these signatures for clinical use.